Stephen Swisher
Overview
Explore the profile of Stephen Swisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
3.
Sewastjanow-Silva M, Xiao L, Gonzalez G, Wang X, Hofstetter W, Swisher S, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611056
Efforts to improve the prognosis for patients with locally advanced esophageal or gastroesophageal junction (GEJ) adenocarcinoma have focused on neoadjuvant approaches to increase the pathological complete response (pathCR) rate, improve...
4.
Altan M, Li Q, Wang Q, Vokes N, Sheshadri A, Gao J, et al.
Front Immunol
. 2023 Dec;
14:1322818.
PMID: 38152395
Trial Registration: ClinicalTrials.gov identifier: NCT03391869.
5.
Francisco-Cruz A, Rocha P, Reuben A, Krishnan S, Das P, Chen R, et al.
Mod Pathol
. 2023 Feb;
36(1):100028.
PMID: 36788067
Our understanding of the molecular mechanisms underlying postsurgical recurrence of non-small cell lung cancer (NSCLC) is rudimentary. Molecular and T cell repertoire intratumor heterogeneity (ITH) have been reported to be...
6.
Feldman H, Zhou N, Deboever N, Hofstetter W, Mehran R, Rajaram R, et al.
JTCVS Open
. 2023 Jan;
12:372-384.
PMID: 36590745
Objectives: Neoadjuvant therapy has been theorized to increase complexity of non-small cell lung cancer resections; however, specific factors that contribute to intraoperative challenges after induction therapy have not been well...
7.
Shenson J, Zafereo M, Lee M, Contrera K, Feng L, Boonsripitayanon M, et al.
Head Neck
. 2022 Dec;
45(3):547-554.
PMID: 36524701
Background: Advanced thyroid disease involving the mediastinum may be managed surgically with a combined transcervical and transthoracic approach. Contemporary analysis of this infrequently encountered cohort will aid the multidisciplinary team...
8.
Akhave N, Zhang J, Bayley E, Frank M, Chiou S, Behrens C, et al.
Lung Cancer
. 2022 Aug;
172:19-28.
PMID: 35973335
Objectives: Pathologists have routinely observed distinct histologic patterns of growth in early-stage lung adenocarcinoma (LUAD), which have been suggested to be associated with prognosis. Herein, we investigated the relationship between...
9.
Ahmed T, Mouhayar E, Song J, Koutroumpakis E, Palaskas N, Yusuf S, et al.
Front Cardiovasc Med
. 2022 Jun;
9:916325.
PMID: 35711368
Aim: This study investigated the factors predicting survival and the recurrence of pericardial effusion (PE) requiring pericardiocentesis (PCC) in patients with cancer. Materials And Methods: We analyzed the data of...
10.
Liu Y, Zhang Z, Rinsurongkawong W, Gay C, Le X, Ning M, et al.
JAMA Netw Open
. 2022 Jun;
5(6):e2215589.
PMID: 35666500
Importance: Consolidative durvalumab after definitive chemoradiation for unresectable locally advanced non-small cell lung cancer (NSCLC) can significantly improve progression-free survival (PFS) and overall survival (OS), as shown in the PACIFIC...